Skip to content
lifestyle.sli.mg
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Innovent Biologics
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
September 28, 2026
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
September 27, 2026
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
September 23, 2026
Innovent Announces 2026 Interim Results and Business Updates
August 25, 2026
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
August 9, 2026
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
August 5, 2026
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
June 8, 2026
World’s First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
June 4, 2026
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
May 31, 2026
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
May 31, 2026
1
2
Next Page
→